LAM-001 for lung scarring with high blood pressure
Part of Lungs & breathing clinical trials.
This trial tests a new medication called LAM-001 for people with high blood pressure in the lungs caused by lung scarring. It aims to see if it can improve symptoms and help you feel better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old (over 70 needs special approval).
- You have been diagnosed with pulmonary hypertension (high blood pressure in the lungs) along with a type of lung scarring (interstitial lung disease).
- Your lung function tests show a forced vital capacity (FVC) less than 65% of predicted and a DLCO (ability to transfer oxygen) above 30%. Or if you had part of a lung removed, the doctor will assess based on remaining lung volume.
- You are currently on a stable dose of pulmonary hypertension medication for at least 90 days.
- You can walk between 100 and 450 meters (about 1 to 5 football fields) in 6 minutes, and two tests show similar results.
- You agree to use effective birth control (if applicable) and not donate blood/eggs/sperm during the study and for 90 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
This trial tests a new medicine called TX000045 for people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug can help improve breathing and daily function.
This study tests a new dry powder inhaled medicine called LIQ861 for people with pulmonary hypertension related to lung scarring (PH-ILD). If you are already taking an inhaled treprostinil treatment but need better control, this trial may help you switch to a potentially easier-to-use version.
This trial tests a new treatment called L606 for people who have both a type of lung disease (ILD) and high blood pressure in the lungs (PH). The goal is to see if it is safe and helps with exercise and breathing.
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
This trial tests an investigational drug called NS-863 for people who have both interstitial lung disease (scarring of the lungs) and pulmonary hypertension (high blood pressure in the lungs). The goal is to see if the drug can help improve your condition.
Hear when a new Pulmonary Hypertension Due to Lung Diseases and Hypoxia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.